Drug intelligence / Profile preview

liraglutide + semaglutide

Development stage: Unknown
Lead developer: Novo Nordisk
Modality: Peptides, Recombinant Proteins and Enzymes
Administration: Subcutaneous, Oral

Overview

This is not a fixed combination drug product but rather two separate GLP-1 receptor agonist medications. Both liraglutide and semaglutide are peptide hormones that mimic the action of glucagon-like peptide-1 (GLP-1). They work by increasing insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and reducing appetite, which helps in managing blood glucose levels and body weight.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on liraglutide + semaglutide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on liraglutide + semaglutide.

Explore the full profile